Perspective Therapeutics CATX Revenue from contracts outside the scope of ASC Topic 606
Revenue from contracts outside the scope of ASC Topic 606 at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomer.
The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Perspective Therapeutics's revenue from contracts outside the scope of asc topic 606.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Perspective Therapeutics's revenue from contracts outside the scope of ASC topic 606?
- Perspective Therapeutics (CATX) reported revenue from contracts outside the scope of ASC topic 606 of $76K in Q1 2026.
- How has Perspective Therapeutics's revenue from contracts outside the scope of ASC topic 606 changed year-over-year?
- Perspective Therapeutics's revenue from contracts outside the scope of ASC topic 606 decreased by 77.8% year-over-year, from $342K to $76K.
- What is the long-term trend for Perspective Therapeutics's revenue from contracts outside the scope of ASC topic 606?
- Over 2 years (2023 to 2025), Perspective Therapeutics's revenue from contracts outside the scope of ASC topic 606 has grown at a -21.5% compound annual growth rate (CAGR), from $1.43M to $884K.
- What does revenue from contracts outside the scope of ASC topic 606 mean?
- This metric represents revenue streams recognized outside the scope of standard customer contracts governed by ASC Topic 606. It typically includes income from sources such as government grants, research collaborations, or licensing agreements that do not meet the criteria for a traditional customer contract. Monitoring this helps investors identify alternative funding sources that support ongoing research and development efforts.